Mattia Galli/LinkedIn
Nov 2, 2025, 05:36
Mattia Galli on Use of Genetic Testing to Guide the Choice of Antiplatelet Drugs
Mattia Galli, Assistant Professor at Sapienza University of Rome, Associate Editor of European Heart Journal, shared on LinkedIn:
”Growing interest in Rome in the use of genetic testing to guide the choice of antiplatelet drugs.
Is the time finally ripe for cardiology to move towards precision drug therapy?
A wonderful meeting and stimulating discussion with colleagues from one of Rome’s most important hospitals, in a session moderated by some of the “teachers” I had the pleasure of meeting during my specialization course.
Francesco Burzotta, Gaetano Antonio Lanza.”
Stay updated with Hemostasis Today.
-
Aug 21, 2026, 21:58Toby Richards: WEHI Trial Solidifies IV Iron as Third-Trimester Standard
-
Aug 21, 2026, 21:51Mehak Trehan: From Reading the Chapter to Writing One
-
Aug 21, 2026, 21:38Ann Reilly: Navigating Postoperative vs. Acute Blood Loss Anemia – A CDI Case Study
-
Aug 21, 2026, 21:29Merlin Crossley: Atomic Precision in Sickle Cell Care – Structural Targeting for Fetal Globin Reactivation
-
Aug 21, 2026, 19:09Aphisit Thongthaisin: Admitted to Sorbonne University’s T2H University Diploma for 2026/2027
-
Aug 21, 2026, 19:07José Luis Ferreiro Gutiérrez: Proud to Be Elected Chairperson-Elect of the ESC Working Group on Thrombosis
-
Aug 21, 2026, 19:00Manuel Monreal: New RIETE Registry Data on VTE Recurrence and Bleeding During Anticoagulation
-
Aug 21, 2026, 18:39Ronak H. Mistry: Updated ASH ITP Guidelines Bring New Guidance for Managing ITP
-
Aug 21, 2026, 18:22Ahmed Bennis: NOAC Use Is Associated With Slower Cognitive Decline in AF and Alzheimer’s Disease